Surgical management of high risk prostate cancer: the Mayo Clinic experience (Q37261960)

19 August 2017

1 reference

title

Surgical management of high risk prostate cancer: the Mayo Clinic experience (English)

1 reference

19 August 2017

1 reference

Stephen A Boorjian

1

1 reference

19 August 2017

Michael L Blute

series ordinal

2

1 reference

19 August 2017

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

26

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

530-532

1 reference

Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Changing nature of high risk patients undergoing radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Patterns of prostate cancer treatment by clinical stage and age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.009

10.1016/J.UROLONC.2008.03.009

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference